The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-07-31 and is reviewed periodically as new material appears.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
== History == The individual subunits of the G protein complex were first identified in 1980 when the regulatory component of adenylate cyclase was successfully purified, yielding three polypeptides of different molecular weights. Initially, it was thought that Gα, the largest subunit, was the major effector regulatory subunit, and that Gβγ was largely responsible for inactivating the Gα subunit and enhancing membrane binding. However, downstream signalling effects of Gβγ were later discovered when the purified Gβγ complex was found to activate a cardiac muscarinic K+ channel. Shortly after, the Gβγ complex associated with a mating factor receptor-coupled G protein in yeast was found to initiate a pheromone response. Although these hypotheses were initially controversial, Gβγ has since been shown to directly regulate as many different protein targets as the Gα subunit. Recently, possible roles of the Gβγ complex in retinal rod photoreceptors have been investigated, with some evidence for the maintenance of Gα inactivation. However, these conclusions were drawn from in vitro experiments under unphysiological conditions, and the physiological role of the Gβγ complex in vision is still unclear. Nevertheless, recent in vivo findings demonstrate the necessity of the transducin Gβγ complex in the functioning of rod photoreceptors under low light conditions.
During Rush's European leg of the Clockwork Angels Tour, the June 8, 2013, show at the Sweden Rock Festival was the group's first festival appearance in 30 years. On August 31, 2011, Rush switched their American distribution from Atlantic Records to the Warner Brothers majority-owned metal label Roadrunner Records. Roadrunner handled American distribution of Time Machine 2011: Live in Cleveland and Clockwork Angels. Anthem/Universal Music would continue to release their music in Canada. On April 18, 2013, Rush were inducted into the Rock and Roll Hall of Fame in Cleveland, Ohio.
Additionally, an influx of alpha-ketoisocaproic acid transported by a monocarboxylate transporter (MCT) across the blood–brain barrier, may deplete glutamate and glutamine in astrocytes, an important type of glial cell, through transamination (via BCAT). Glutamate levels are maintained in the brain by BCAA metabolism functions and if not properly maintained can lead to neurological problems that are seen in MSUD individuals. Another aspect of MSUD pathology involves the impact of elevated BCAA and BCKA on sodium-potassium ATPase activity, leading to electrolyte imbalances that contribute to cerebral edema and seizures. High leucine levels can disrupt water homeostasis in the brain's subcortical gray matter, potentially causing cerebral edema due to hyponatremia linked to increased levels of atrial natriuretic peptide and vasopressin.
Sources: en.wikipedia.org
Seydina Oumar Sy - Minister of Foreign Affairs Thierno Alassane Sall - Former Minister of Energy, Infrastructure, Land Transport, Senegal. Fatma Samoura - Diplomat, First Female secretary General of FIFA. Aïssata Tall Sall- Minister of Foreign Affairs; Senegal Zahra Iyane Thiam - Former Minister of Microfinance and Social and Solidarity Economy, Senegal. Abdoulkader Thiam Abdallahi Mahmoud Abdoulaye Ba Adama Ba Ahmed Sidibé - Mauritanian Football Manager and former player Aly Abeid— Football player; Mauritania Houssen Abderrahmane Bilal Sidibé - Mauritanian football player Ibrahim Ba Issa Ba Issiar Dia Mohamed Dellahi Yali Moussa Sow- Football player Pape Habib Sow Aïssata Tall Sall - Minister of Foreign Affairs, Senegal Abdou Diallo - Senegalese professional footballer who plays for RB Leipzig. Kalidou Koulibaly - Senegalese professional footballer who plays for Al Hilal SFC. Bambo Diaby El Hadji Ba Lamine Ba Demba Ba El Mami Tetah Papa Malick Ba Mohamed Saqr Mouhamadou Dabo Mamadou Fall Idrissa Thiam Djeidi Gassama Ousseynou Ba
Hamish de Bretton-Gordon, a British chemical weapons expert and former commanding officer of the UK's Joint Chemical, Biological, Radiation and Nuclear Regiment and its NATO equivalent, "dismissed" suggestions that Novichok agents could be found in other places in the former Soviet Union such as Uzbekistan and has asserted that Novichok agents were produced only at Shikhany in Saratov Oblast, Russia. Mirzayanov also says that it was at Shikhany, in 1973, that scientist Pyotr Petrovich Kirpichev first produced Novichok agents; Vladimir Uglev joined him on the project in 1975. According to Mirzayanov, while production took place in Shikhany, the weapon was tested at Nukus between 1986 and 1989. Following the poisoning of the Skripals, former head of the GosNIIOKhT security department Nikolay Volodin confirmed in an interview to Novaya Gazeta that there have been tests at Nukus, and said that dogs were used. In May 2018, the Irish Independent reported that "Germany's foreign intelligence service secured a sample of the Soviet-developed nerve agent Novichok in the 1990s and passed on its knowledge to partners including Britain and the US, according to German media reports." The sample was analysed in Sweden. Small amounts of the Novichok nerve agent were subsequently produced in some NATO countries for test purposes.
==== Biden administration ==== On 13 February 2021, the White House said it had "deep concerns" about both the way the WHO's findings were communicated and the process used to reach them. Mirroring concerns raised by the Trump administration, National Security Advisor Jake Sullivan stated that it was essential that the WHO-convened report be independent and "free from alteration by the Chinese government". On 14 April 2021, the Director of National Intelligence Avril Haines, along with other Biden administration officials, said that they had not ruled out the possibility of a laboratory accident as the origin of the COVID-19 virus. On 26 May 2021, President Joe Biden directed the U.S. intelligence community to produce a report within 90 days on whether the COVID-19 virus originated from human contact with an infected animal or from an accidental lab leak, stating his national security staff said there is insufficient evidence to determine either hypothesis to be more likely. On 26 August 2021, the Office of the Director of National Intelligence released an unclassified summary of their findings, with the main point being that the report remained inconclusive as to the origin of the virus, with intelligence agencies divided on the question. The report also concluded that the virus was most likely not genetically engineered, and that China had no foreknowledge of the virus prior to the outbreak.
Sources: en.wikipedia.org
=== Burial depth === It is a common misconception that graves must be dug to a depth of six feet (1.8 metres). This is reflected in the common euphemism for death of six feet under. In fact, graves are rarely dug to this depth except when it is intended to later bury a further coffin or coffins on top of the first one. In such cases, more than six feet may be dug, to provide the required depth of soil above the top coffin. In the United States, there is no nationwide regulation of burial depth. Each local authority is free to determine its own rules. Requirements for depth can vary according to soil type and by method of burial. California, for instance, requires only 19 inches of soil above the top of the coffin, but more commonly 30 to 36 inches are required in other places. In some areas, such as central Appalachia, graves were indeed once dug to a depth of six feet to prevent the body being disturbed by burrowing animals. However, this was unnecessary once metal caskets and concrete vaults started to be used. In the United Kingdom, soil is required to be to a depth of three feet above the highest point of the coffin, unless the burial authority consider the soil to be suitable for a depth of only two feet. The earliest known reference to a requirement for a six-foot burial occurred in 1665 during the Great Plague of London.
== Mechanism of action == Testosterone patches works by releasing the hormone testosterone through the skin into the bloodstream. In women, testosterone is naturally produced by the ovaries and the adrenal gland. However, levels of the hormone decline with age, sometimes more after menopause. Testosterone therapy is systemic and needs to be applied over a period of weeks or months to have an effect. P&G licensed the treatment to Watson Pharmaceuticals.
If we can't hold ourselves up as an example of how to treat people with dignity and respect, we can't ask that other nations do that to our soldiers." On May 1, 2004, photos of prisoners at Abu Ghraib prison in Iraq being abused and humiliated by United States soldiers provoke an international outrage. Furthering the charges, excerpts from the Abu Ghraib Taguba report were published on May 3, 2004. The report documented: the sodomizing of a prisoner with a chemical light, pouring phosphoric liquid on detainees, rape of a female prisoner, forced masturbation, "ghost detainees" moved around to avoid the Red Cross, and many other abuses. The release of the photographs and reports had led to renewed calls for investigations into the abuses reported in other US military prisons, such as Camp X-Ray and Camp Delta. On May 14, 2004, reporters for the Guardian documented a coercive technique which soldiers called "bitch in a box". The prisoner was shoved into the trunk of a car on a hot day, and driven around until the prisoner was near ready to pass out. Another technique documented was "waterboarding", which involves water being poured over a cloth covering the face and breathing passages of an immobilized captive, causing the individual to experience the sensation of drowning. They also interviewed many soldiers not involved in the current scandal, who claimed that they were taught to use sleep deprivation, to stage mock executions, and to use other procedures. One platoon leader who objected to these practices was reportedly told that his stand could end his military career.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.